Tygacil

Risk of increase in all-cause mortality; reserve for use when alternatives are not suitable. Monitor for hepatic dysfunction and pancreatitis; consider discontinuing if occurs. Ventilator-associated pneumonia. Complicated intra-abdominal infections secondary to intestinal perforation: avoid monotherapy (sepsis/septic shock may develop). Monitor blood coagulation parameters (including fibrinogen) at baseline and during treatment. Severe hepatic impairment. Risk of tooth discoloration, enamel hypoplasia, and reversible bone growth inhibition (during 2^nd/3^rd trimester of pregnancy, infancy, and childhood up to age 8yrs). Pregnancy (2^nd/3^rd trimester). Nursing mothers (avoid if therapy >3 weeks): may consider interrupting breastfeeding and pumping and discarding breastmilk during and for 9 days after the last dose.